Abenavoli L, Milic N, Beaugrand M

Language: English
References: 15
Page: 152-155
PDF size: 135.51 Kb.

ABSTRACT

Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed severe drug-induced hepatotoxicity during the treatment with CPA. The case, presenting sub-acute hepatitis, was characterized by a rapid evolution of cirrhosis and a protracted activity during the period of a few months despite the treatment withdrawal and an apparent benefits of corticosteroids, suggesting their indication in life threatening cases.

REFERENCES

1. Chodak G, Gomella L, Phung de H. Combined androgen blockade in advanced prostate cancer: looking back to move forward. Clin Genitourin Cancer 2007; 5: 371-8.

2. Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis SP. Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J Gastroenterol 2006; 12: 7551-5.

3. Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 2011; 10: 93-8.

4. Thole Z, Manso G, Salgueiro E, Revuelta P, Hidalgo A. Hepatotoxicity induced by antiandrogens: a review of the literature. Urol Int 2004; 73: 289-95.

5. Savidou I, Deutsch M, Soultati AS, Koudouras D, Kafiri G, Dourakis SP. Hepatotoxicity induced by cyproterone acetate: a report of three cases. World J Gastroenterol 2006; 12: 7551-5.

6. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66(6): 758-66.

7. Watanabe S, Yamasaki S, Tanae A, Hibi I, Honna T. Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc comitte on androcur users. Lancet 1994; 344: 1567-8.

8. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology 2010; 52: 748-61.

9. Kasper P. Cyproterone acetate: a genotoxic carcinogen? Pharmacol Toxicol 2001; 88: 223-31.

10. Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N. Monotherapy in advanced prostate cancer: an overview. Exp Oncol 2004; 26: 185-91.

11. Friedman G, Lamoureux E, Sherker AH. Fatal fulminant hepatic failure due to cyproterone acetate. Dig Dis Sci 1999; 44: 1362-3.

12. Manso G, Thole Z, Salgueiro E, Revuelta P, Hidalgo A. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system. Pharmacoepidemiol Drug Saf 2006; 15: 253-9.

13. Miquel M, Soler A, Vaqué A, Ojanguren I, Costa J, Planas R. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int 2007; 27: 1144-7.

14. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011; 56: 958-76.

15. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.